200+ Free USMLE Step 3 Practice Questions

Pass your United States Medical Licensing Examination Step 3 exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

95-98% Pass Rate

200+ Questions

100% Free

1 / 200

Question 1

Score: 0/0

A new screening test for colorectal cancer is being evaluated. In a study of 10,000 patients, the test results were compared to colonoscopy (gold standard). The screening test was positive in 180 patients, of whom 90 had cancer on colonoscopy. The test was negative in 9,820 patients, of whom 40 had cancer on colonoscopy. What is the negative predictive value of this screening test?

89.5%

90.0%

95.5%

99.6%

to track

2026 Statistics

Key Facts: USMLE Step 3 Exam

95-98%

US/Canadian MD/DO Pass Rate

USMLE 2023

412

Total MCQs

232 Day 1 + 180 Day 2

CCS Cases (Day 2)

16h

Total Testing Time

7h Day 1 + 9h Day 2

198

Passing Score

Scaled 3-digit score

$955

Exam Fee

2026 USMLE Fee Schedule

USMLE Step 3 is the final licensing exam for physicians, typically taken during residency. It has a 95-98% first-time pass rate for US/Canadian MD and DO graduates. The 2-day exam includes 412 multiple-choice questions plus 13 Computer-Based Case Simulations. Passing Step 3 is required for medical licensure in all US jurisdictions. The exam emphasizes clinical decision-making, patient management, and biostatistics.

Sample USMLE Step 3 Practice Questions

Try these sample questions to test your USMLE Step 3 exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 200+ question experience with AI tutoring.

1A new screening test for colorectal cancer is being evaluated. In a study of 10,000 patients, the test results were compared to colonoscopy (gold standard). The screening test was positive in 180 patients, of whom 90 had cancer on colonoscopy. The test was negative in 9,820 patients, of whom 40 had cancer on colonoscopy. What is the negative predictive value of this screening test?

A.89.5%

B.90.0%

C.95.5%

D.99.6%

Explanation: To calculate negative predictive value (NPV), we need: True Negatives (TN) / (True Negatives + False Negatives). From the data: True Positives (TP) = 90, False Positives (FP) = 90 (180 total positive - 90 TP). False Negatives (FN) = 40, True Negatives (TN) = 9,780 (9,820 total negative - 40 FN). NPV = TN / (TN + FN) = 9,780 / (9,780 + 40) = 9,780 / 9,820 = 99.6%.

2A pharmaceutical company is testing a new drug for migraine prevention. The primary outcome is reduction in migraine frequency. The study enrolls 400 patients: 200 receive the new drug and 200 receive placebo. After 6 months, 120 patients in the treatment group and 80 in the placebo group show ≥50% reduction in migraine frequency. What is the number needed to treat (NNT)?

A.2

B.3

C.4

D.5

Explanation: NNT = 1 / Absolute Risk Reduction (ARR). Treatment event rate = 120/200 = 0.60 (60%). Control event rate = 80/200 = 0.40 (40%). ARR = 0.60 - 0.40 = 0.20 (20%). NNT = 1 / 0.20 = 5. This means you need to treat 5 patients with the new drug to prevent one additional case of inadequate migraine control compared to placebo.

3A case-control study examines the association between NSAID use and peptic ulcer disease. Cases (n=200) are patients with confirmed peptic ulcers; controls (n=400) are age-matched patients without ulcers. The study finds that 120 cases and 80 controls reported regular NSAID use. What measure of association can be calculated from this study design?

A.Relative risk

B.Odds ratio

C.Attributable risk

D.Incidence rate

Explanation: Odds ratio is the appropriate measure of association for case-control studies. In this design, subjects are selected based on outcome status (disease presence/absence), not exposure status. Odds of exposure among cases = 120/80 = 1.5. Odds of exposure among controls = 80/320 = 0.25. Odds ratio = 1.5/0.25 = 6.0. Relative risk and incidence require knowing disease incidence, which cannot be calculated from case-control data.

4A randomized controlled trial of a new anticoagulant for stroke prevention in atrial fibrillation reports the following results: 2.5% annual stroke rate in the treatment group vs. 4.0% in the warfarin control group (p=0.02). The 95% confidence interval for the relative risk reduction is 15% to 55%. Which conclusion is most appropriate?

A.The new drug is superior to warfarin

B.The new drug is equivalent to warfarin

C.The new drug is non-inferior to warfarin

D.No conclusion can be drawn due to wide confidence intervals

Explanation: The p-value of 0.02 (<0.05) indicates statistical significance. The relative risk reduction (RRR) = (4.0% - 2.5%) / 4.0% = 37.5%. Since the entire 95% CI (15-55%) for RRR is above 0 and does not cross the null value, and the p-value is significant, we can conclude the new drug is superior to warfarin. Non-inferiority and equivalence trials require different study designs with pre-specified margins.

5A screening program for breast cancer using mammography is implemented in a community. The test has 85% sensitivity and 90% specificity. If the prevalence of breast cancer in this population is 1%, what is the probability that a woman with a positive screening test actually has breast cancer?

A.1%

B.8%

C.15%

D.79%

Explanation: Use a 2×2 table with 1,000 women: Disease prevalence = 1% (10 with cancer, 990 without). Sensitivity = 85% → 8.5 true positives (round to 9), 1.5 false negatives. Specificity = 90% → 891 true negatives, 99 false positives. Total positives = 9 + 99 = 108. Positive Predictive Value = TP / All positives = 9/108 = 8.3% ≈ 8%. This illustrates how even with good test characteristics, low prevalence leads to many false positives.

6In a meta-analysis of 15 randomized trials comparing two antihypertensive medications, a funnel plot shows asymmetry with smaller studies disproportionately favoring the newer agent. What is the most likely explanation for this finding?

A.Publication bias

B.Heterogeneity between studies

C.Random error

D.Confounding by indication

Explanation: Funnel plot asymmetry, particularly with smaller studies showing exaggerated treatment effects, is characteristic of publication bias (or the "file drawer problem"). Negative results from small studies are less likely to be published. Other causes of funnel plot asymmetry include heterogeneity, poor methodological quality in smaller studies, or true differences in treatment effect by study size. Egger's test can statistically assess funnel plot asymmetry.

7A cohort study follows 5,000 smokers and 5,000 non-smokers for 10 years to assess lung cancer incidence. At year 5, 20% of smokers quit smoking. At the end of the study, 250 smokers and 25 non-smokers developed lung cancer. Which of the following best describes the impact of the smokers who quit?

A.Selection bias

B.Information bias

C.Confounding

D.Lead-time bias

Explanation: When participants change their exposure status during follow-up, this creates confounding if the change is related to both the original exposure and outcome. Smokers who quit may differ systematically from continuing smokers (e.g., health-conscious, developed symptoms). This change in exposure status during follow-up complicates the intention-to-treat analysis and can bias the association between smoking and lung cancer.

8A 45-year-old man is brought to the emergency department after a motor vehicle accident. He has multiple injuries and requires emergent surgery. The patient is unconscious and no family members are present. According to emergency consent doctrine, what is the appropriate next step?

A.Wait for family to arrive before proceeding

B.Proceed with treatment under implied consent

C.Obtain a court order

D.Contact the hospital ethics committee

Explanation: The emergency consent doctrine (implied consent) permits treatment without explicit consent when: (1) immediate intervention is necessary to prevent death/serious harm, (2) the patient cannot consent, and (3) no legally authorized surrogate is available. A reasonable person would consent to emergent, life-saving treatment. Documentation of efforts to contact family and the rationale for proceeding is essential.

9A 16-year-old girl requests oral contraceptives during a clinic visit. She asks that her parents not be informed. In which situation may the physician legally provide treatment without parental consent?

A.Never; minors always require parental consent

B.If state law permits contraceptive services for minors

C.Only if the minor is pregnant

D.Only with court authorization

Explanation: Minor consent laws vary by state, but many states specifically allow minors to consent to contraceptive services, STI testing/treatment, prenatal care, and substance abuse treatment without parental involvement. This supports public health goals by ensuring access to preventive care. The physician should be familiar with applicable state laws and document the encounter appropriately while encouraging the minor to involve parents when possible.

10A 68-year-old man with advanced dementia is admitted to the hospital with pneumonia. His wife, who is his healthcare proxy, requests that antibiotics be withheld based on his previously stated wish to avoid aggressive treatment. The patient's adult children disagree and demand antibiotics be started. What is the most appropriate action?

A.Follow the wife's decision as the designated proxy

B.Follow the children's wishes as they represent the majority

C.Request a court to appoint a guardian

D.Treat with antibiotics and address conflict later

Explanation: A designated healthcare proxy (durable power of attorney for healthcare) has legal authority to make medical decisions when the patient lacks capacity, superseding family consensus. The proxy's decision should reflect the patient's previously expressed wishes (substituted judgment) or best interests. If the proxy's decision appears not to reflect the patient's wishes, ethics consultation may help resolve disputes, but the proxy's authority prevails unless challenged in court.

About the USMLE Step 3 Exam

USMLE Step 3 is the final examination in the USMLE sequence. Day 1 (Foundations of Independent Practice - FIP) includes 232 multiple-choice questions assessing biostatistics, epidemiology, social sciences, and foundational clinical sciences. Day 2 (Advanced Clinical Medicine - ACM) includes 180 multiple-choice questions plus 13 Computer-Based Case Simulations (CCS) assessing diagnosis and management of patient cases. The exam assesses the ability to apply medical knowledge and understanding of biomedical and clinical science essential for the unsupervised practice of medicine.

Questions

412 scored questions

Time Limit

2 days (7 hours Day 1, 9 hours Day 2)

Passing Score

198 (scaled 3-digit score)

Exam Fee

$955 (FSMB (Federation of State Medical Boards) and NBME)

USMLE Step 3 Exam Content Outline

11-13%

Biostatistics & Epidemiology

Study design, statistical interpretation, screening tests, risk assessment, public health principles

7-9%

Social Sciences

Medical ethics, professionalism, cultural competence, health systems, patient safety, communication

70-75%

Clinical Sciences

All organ systems with emphasis on diagnosis and management across internal medicine, surgery, pediatrics, psychiatry, OB/GYN, and emergency medicine

Day 1

Foundations of Independent Practice (FIP)

232 MCQs covering biostatistics, epidemiology, social sciences, and foundational clinical sciences

Day 2

Advanced Clinical Medicine (ACM)

180 MCQs plus 13 Computer-Based Case Simulations covering diagnosis, management, and patient care

How to Pass the USMLE Step 3 Exam

What You Need to Know

Passing score: 198 (scaled 3-digit score)
Exam length: 412 questions
Time limit: 2 days (7 hours Day 1, 9 hours Day 2)
Exam fee: $955

Keys to Passing

Complete 500+ practice questions
Score 80%+ consistently before scheduling
Focus on highest-weighted sections
Use our AI tutor for tough concepts

USMLE Step 3 Study Tips from Top Performers

1Master biostatistics and epidemiology - these are heavily tested on Day 1 and many residents under-prepare

2Practice Computer-Based Case Simulations extensively - these are unique to Step 3 and require specific strategies

3Focus on clinical management algorithms - Step 3 emphasizes what to do next in patient care

4Review all major organ systems with emphasis on internal medicine, emergency medicine, and ambulatory care

5Understand pharmacotherapy - drug selection, dosing, monitoring, and adverse effects are frequently tested

Frequently Asked Questions

What is the USMLE Step 3 pass rate?

First-time pass rates for US/Canadian MD and DO graduates are approximately 95-98%. International medical graduates have lower pass rates around 85-90%. Step 3 is typically taken during the first year of residency (PGY-1).

How is USMLE Step 3 scored?

Step 3 uses a 3-digit scaled scoring system with a passing score of 198. Your score is based on performance across both days, with Day 2 case simulations contributing significantly to the final score.

How many questions are on USMLE Step 3?

Day 1 (FIP) has 232 multiple-choice questions over approximately 7 hours. Day 2 (ACM) has 180 multiple-choice questions plus 13 Computer-Based Case Simulations over approximately 9 hours. Total testing time is about 16 hours across 2 days.

When should I take USMLE Step 3?

Most residents take Step 3 during their PGY-1 year after completing at least 6 months of clinical training. Some states require passing Step 3 for full medical licensure by the end of PGY-2 or PGY-3.

What is the best way to prepare for Step 3?

Use UWorld Step 3 question bank, NBME practice exams, and CCS case simulation practice. Focus on clinical decision-making, patient management algorithms, and biostatistics. Many residents study 4-6 weeks part-time during residency.

Can I retake Step 3 if I fail?

Yes, you can retake Step 3 up to 4 times total, with a maximum of 3 attempts within a 12-month period. You must wait 28 days between attempts. However, failing Step 3 may impact residency progression and medical licensure.